CVS · Earnings call · 2026Q2T · Full report

GLP-1 Distribution Expansion

CVS HEALTH Corp · 2026-08-05 · Importance 31 · Surprise 42 · In source text

Demand for GLP-1 therapies for weight loss is growing, with consumers prioritizing affordability, access and convenience. CVS Health is expanding access through Caremark formulary actions, MinuteClinic’s 24/7 virtual weight-management offering, cash-pay fulfillment through CVS Pharmacy, and manufacturer relationships with Eli Lilly and Novo Nordisk. Later in 2026, eligible Zepbound and Foundayo patients will be able to obtain cash-pay prescriptions for same-day pickup through the CVS app or stores, while existing offerings include oral and injectable Wegovy. Medicare Bridge is also intended to help seniors navigate access to GLP-1 therapies, and CVS expects the opportunity to contribute to Pharmacy and Consumer Wellness growth.

Key facts

Impact estimates

metricdirectionstageexpectedbasis
revenuepositivecommitted—New partnership with Eli Lilly will allow eligible Zepbound and Foundayo patients to access cash pay pricing for same-day pickup directly…
revenuepositiverealized—Launched a MinuteClinic weight management offering in Q2 at $49 per visit and reduced price to $29 going forward; visits available 24/7…
revenuepositivecommitted—Eligible patients can access GLP-1 therapies for as little as $149 through cash pay options via CVS Pharmacy's omnichannel fulfillment.
revenuepositivecommitted—CVS Pharmacy will dispense oral and injectable Wegovy through existing relationship with Novo.
revenuepositiverealized—Launched Medicare Bridge last month to help seniors navigate the program and access GLP-1 therapies more easily.